Jenburkt Pharmaceuticals (524731) Stock Overview
Researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
524731 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Jenburkt Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,074.90 |
| 52 Week High | ₹1,410.00 |
| 52 Week Low | ₹920.20 |
| Beta | 0.36 |
| 1 Month Change | -7.57% |
| 3 Month Change | -21.98% |
| 1 Year Change | 8.31% |
| 3 Year Change | 95.92% |
| 5 Year Change | 187.71% |
| Change since IPO | 15,039.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524731 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.2% | 1.4% | 1.5% |
| 1Y | 8.3% | -7.2% | -4.7% |
Return vs Industry: 524731 exceeded the Indian Pharmaceuticals industry which returned -7.2% over the past year.
Return vs Market: 524731 exceeded the Indian Market which returned -4.7% over the past year.
Price Volatility
| 524731 volatility | |
|---|---|
| 524731 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: 524731 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524731's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 779 | Ashish Bhuta | jenburkt.com |
Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names.
Jenburkt Pharmaceuticals Limited Fundamentals Summary
| 524731 fundamental statistics | |
|---|---|
| Market cap | ₹4.74b |
| Earnings (TTM) | ₹324.36m |
| Revenue (TTM) | ₹1.55b |
Is 524731 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524731 income statement (TTM) | |
|---|---|
| Revenue | ₹1.55b |
| Cost of Revenue | ₹310.58m |
| Gross Profit | ₹1.24b |
| Other Expenses | ₹911.89m |
| Earnings | ₹324.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 28, 2025
| Earnings per share (EPS) | 73.50 |
| Gross Margin | 79.92% |
| Net Profit Margin | 20.97% |
| Debt/Equity Ratio | 2.3% |
How did 524731 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 18:34 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jenburkt Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |